NovaBridge Biosciences NBP
1.38
(0.07)
(4.83%)
as of 25 Sep
- Market cap
- $172.8M
- P/E
- 0.0×
Follow NBP
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Mar '25 | Jun '25 | Sep '25 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
21.75 | 22.54 | 14.19 | 7.36 | |
Current Ratio |
22.35 | 22.82 | 14.47 | 7.64 | |
Net Debt/EBITDA |
32.02 | 23.28 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 1.42 | 0.00 | 0.00 | |
Capex/Depreciation |
— | 0.09 | 0.00 | (1.64) | |
Interest Coverage |
0.00 | 0.00 | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | — | — | |
Operating CF per Share |
0.00 | (0.10) | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | (0.10) | 0.00 | 0.00 | |
Cash per Share |
2.14 | 2.03 | 0.00 | 0.00 | |
Shareholders Equity per Share |
2.52 | 2.41 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | — | |
Book value per Share |
2.52 | 2.41 | 0.00 | 0.00 | |
Free Cash Flow |
— | (7.80) | 1.84 | (33.92) | |
Working Capital |
165.48 | 160.29 | 216.68 | 172.08 | |
Capital Expenditures |
— | 0.04 | 0.00 | (0.99) | |
Net Current Asset Value |
162.63 | 157.67 | 214.28 | 167.57 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | — | — | |
| Other line items | |||||
Average Assets |
104.47 | 230.27 | 255.05 | 222.11 | |
Average Common Equity |
220.17 | 216.68 | 238.40 | 201.13 |
Columns are period end dates